Table of Contents
Apixaban is a widely used oral anticoagulant that belongs to the class of direct factor Xa inhibitors. It plays a crucial role in the prevention and treatment of thromboembolic disorders. Understanding its pharmacology is essential for students preparing for exams in medicine, pharmacy, and related fields.
Mechanism of Action
Apixaban selectively inhibits factor Xa, an enzyme that plays a central role in the coagulation cascade. By inhibiting factor Xa, apixaban prevents the conversion of prothrombin to thrombin, thereby reducing fibrin clot formation. This targeted action makes it effective in preventing clot formation without significantly affecting other pathways.
Pharmacokinetics
Apixaban is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 3-4 hours post-dose. It has a bioavailability of about 50%. The drug is approximately 87% bound to plasma proteins, primarily albumin. It undergoes hepatic metabolism mainly via CYP3A4 and is eliminated through renal and fecal routes.
Indications
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
- Treatment of deep vein thrombosis (DVT)
- Treatment of pulmonary embolism (PE)
- Prevention of recurrent DVT and PE
Dosage and Administration
The typical dose for stroke prevention in atrial fibrillation is 5 mg twice daily. Dose adjustments are necessary for patients with renal impairment, age over 80 years, or body weight less than 60 kg. It should be taken orally, with or without food, at the same times daily to maintain consistent blood levels.
Adverse Effects
Common adverse effects include bleeding, which can range from minor to severe. Other side effects may include nausea, anemia, and hypersensitivity reactions. Bleeding risk is heightened in patients with renal impairment, concomitant use of other anticoagulants, or history of bleeding disorders.
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) increase apixaban levels
- Strong CYP3A4 inducers (e.g., rifampin) decrease effectiveness
- Other anticoagulants and antiplatelet agents increase bleeding risk
Monitoring and Precautions
Routine coagulation monitoring is not required with apixaban, but renal function should be assessed periodically. Patients should be monitored for signs of bleeding and advised to report any unusual bleeding or bruising immediately. Use with caution in patients with active bleeding or significant liver disease.
Conclusion
Apixaban is a potent and selective factor Xa inhibitor with a favorable safety profile for the prevention and treatment of thromboembolic disorders. Its pharmacological properties make it a preferred choice in many clinical settings. Understanding its mechanism, pharmacokinetics, and safety considerations is vital for effective exam preparation and clinical application.